Review
Oncology
Alisa N. Blumenthaler, Mara B. Antonoff
Summary: Around half of NSCLC patients have metastatic disease at diagnosis, some with limited metastatic sites termed oligometastasis. Aggressive treatment of oligometastasis has shown improved survival rates, but the lack of a universal definition hinders comparison between studies.
Review
Oncology
Katie Jasper, Brendon Stiles, Fiona McDonald, David A. Palma
Summary: This review summarizes the benefits of local ablative therapies in patients with oligometastatic disease in non-small-cell lung cancer and discusses a modern framework for treatment management.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Review
Oncology
Yi-Hsing Chen, Ue-Cheung Ho, Lu-Ting Kuo
Summary: Oligometastatic non-small-cell lung cancer (NSCLC) is a distinct group of patients that could benefit from curative-intent treatment to improve clinical outcomes. Various treatment procedures have been developed for different oligometastatic sites. The proposed uniform definition for oligometastases and ongoing trials may enhance patient selection and evaluation of treatment effectiveness.
Review
Oncology
Suli Zhang, Qian Sun, Feng Cai, Hui Li, Yufu Zhou
Summary: This review analyzes treatment strategies and prognostic factors for patients with oligometastatic non-small cell lung cancer (OM-NSCLC), with a focus on the importance of local ablation therapy (LAT) as a significant treatment component.
FRONTIERS IN ONCOLOGY
(2022)
Review
Oncology
Patricia Mae G. Santos, Xingzhe Li, Daniel R. Gomez
Summary: The study summarizes the clinical evidence and potential considerations for local consolidative therapy (LAT) and stereotactic ablative body radiotherapy (SABR) in the treatment of oligometastatic non-small cell lung cancer (NSCLC), and highlights potential avenues for further research.
Article
Oncology
Caleb J. Euhus, Taylor R. Ripley, Cristian G. Medina
Summary: This article clarifies the concept and definition of oligometastatic non-small cell lung cancer (NSCLC) and reviews the current results in the use of surgery for its management. Oligometastatic NSCLC refers to a subgroup of patients with limited metastases, who seem to have a slower disease progression compared to those with widespread metastases. A missed opportunity to improve survival may occur if palliative systemic therapy is prioritized over local aggressive treatment for these select patients.
Article
Cardiac & Cardiovascular Systems
Bor-Shiuan Shyr, Chien-Sheng Huang, Hui-Shan Chen, Po-Kuei Hsu, Chao-Hua Chiu, Han-Shui Hsu, Chun-Ming Tsai, Yuh-Min Chen
Summary: This study aimed to investigate the impact of primary lung resection and systemic treatment on disease progression and survival in patients with oligometastatic NSCLC. The results showed no significant differences in perioperative complications, hospital length of stay, disease progression, overall death, median PFS, and OS between patients who received primary lung resection and systemic treatment. It was also found that patients with single-organ metastasis had significantly longer PFS and OS than those with oligometastases. Nonsolitary metastasis was identified as the only independent predictor of PFS.
ANNALS OF THORACIC SURGERY
(2022)
Review
Oncology
Raphael S. Werner, Isabelle Opitz
Summary: In the context of non-small cell lung cancer, a multidisciplinary approach is crucial for successful implementation of local aggressive therapy (LAT) in oligometastatic disease. Patient selection and treatment allocation are key challenges, with criteria for selecting patients including characteristics of the primary tumor and metastases, response to treatment, molecular features, and mediastinal lymph node involvement. Success of LAT relies on accurate patient selection criteria.
Article
Oncology
Gregory D. Jones, Harry B. Lengel, Meier Hsu, Kay See Tan, Raul Caso, Amanda Ghanie, James G. Connolly, Manjit S. Bains, Valerie W. Rusch, James Huang, Bernard J. Park, Daniel R. Gomez, David R. Jones, Gaetano Rocco
Summary: Surgical resection of the primary tumor in patients with oligometastatic non-small cell lung cancer can lead to encouraging long-term survival, especially in those who undergo neoadjuvant therapy and have limited intrathoracic disease.
Article
Cardiac & Cardiovascular Systems
Kimihiro Shimizu, Yoichi Ohtaki, Kenji Suzuki, Hiroshi Date, Motohiro Yamashita, Toshihiko Iizasa, Hiroyuki Ito, Kenichi Yoshimura, Morihito Okada, Masayuki Chida
Summary: The study found that pathological nodal stage was an independent prognosticator in the chemoradiotherapy or conventional external beam group, while age 70 years and greater was the only independent prognosticator in the stereotactic body radiotherapy or ion beam radiotherapy group. Overall, patients undergoing salvage surgery can have reasonable outcomes.
ANNALS OF THORACIC SURGERY
(2021)
Review
Oncology
David L. Billing, Andreas Rimner
Summary: Oligometastatic cancer is characterized by a limited number of metastatic deposits, with more favorable survival outcomes compared to patients with widespread disease. Local ablative therapy directed at metastatic deposits, such as radiation therapy, may further improve survival outcomes in oligometastatic lung cancer patients. Studies have shown benefits in progression-free survival and overall survival with the addition of radiation therapy as LAT in oligometastatic lung cancer.
Review
Oncology
Atallah Baydoun, VeAnn L. Lee, Tithi Biswas
Summary: Oligometastatic non-small cell lung cancer (NSCLC) is an intermediate state between localized and widely metastatic NSCLC, and aggressive treatment combining systemic therapy and local therapy can yield favorable outcomes. Personalized treatment approaches with targeted therapies, immune checkpoint inhibitors, and local ablative therapy are recommended based on the individual patient's characteristics.
Review
Oncology
Joe Y. Chang, Vivek Verma
Summary: This review discusses the use of local therapy for oligometastatic and oligoprogression NSCLC, including the current status of data, controversies, and unresolved issues. It touches on the role of local therapy in the context of targeted therapies and immunotherapy, refining patient selection, advantages and disadvantages of different treatment modalities, and optimizing radiotherapy techniques.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
(2022)
Review
Oncology
Akira Hamada, Junichi Soh, Tetsuya Mitsudomi
Summary: Salvage surgery can be considered as an effective treatment option for patients with locally advanced lung cancer, especially for those with late local recurrence or significant metabolic response. In certain conditions, the accumulation of real-world evidence may be necessary for further evaluation, as phase III trials are often difficult to conduct.
TRANSLATIONAL LUNG CANCER RESEARCH
(2021)
Article
Cardiac & Cardiovascular Systems
Allison L. Rosenstein, Alexandra L. Potter, Priyanka Senthil, Vignesh Raman, Arvind Kumar, Ashok Muniappan, Mark F. Berry, Chi-Fu Jeffrey Yang
Summary: This study evaluated the outcomes of delayed resection after radiation therapy for non-small cell lung cancer. The results showed acceptable perioperative outcomes among a highly selected patient cohort.
ANNALS OF THORACIC SURGERY
(2023)
Article
Oncology
Umair Mahmood, Andrew Bang, Yu-Hui Chen, Raymond H. Mak, Jochen H. Lorch, Glenn J. Hanna, Mizuki Nishino, Claire Manuszak, Emily M. Thrash, Mariano Severgnini, Matthew Sanborn, Vishwajith Sridharan, Danielle N. Margalit, Roy B. Tishler, Paul M. Busse, Henning Willers, Harvey J. Mamon, Hyung-Jin Yoo, Sara Pai, Lori J. Wirth, Robert Haddad, Nicole G. Chau, Jonathan D. Schoenfeld
Summary: This study evaluated the safety and efficacy of pembrolizumab with or without radiation therapy in patients with adenoid cystic carcinoma. While no objective responses were observed, a majority of patients achieved stable disease with decreased tumor growth rate and half experienced clinical benefit exceeding 6 months. Favorable local responses were also observed within the radiation field, highlighting the need for additional strategies to delay progression and improve response.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2021)
Article
Genetics & Heredity
Ryan Sun, Miao Xu, Xihao Li, Sheila Gaynor, Hufeng Zhou, Zilin Li, Yohan Bosse, Stephen Lam, Ming-Sound Tsao, Adonina Tardon, Chu Chen, Jennifer Doherty, Gary Goodman, Stig E. Bojesen, Maria T. Landi, Mattias Johansson, John K. Field, Heike Bickeboeller, H-Erich Wichmann, Angela Risch, Gadi Rennert, Suzanne Arnold, Xifeng Wu, Olle Melander, Hans Brunnstrom, Loic Le Marchand, Geoffrey Liu, Angeline Andrew, Eric Duell, Lambertus A. Kiemeney, Hongbing Shen, Aage Haugen, Mikael Johansson, Kjell Grankvist, Neil Caporaso, Penella Woll, M. Dawn Teare, Ghislaine Scelo, Yun-Chul Hong, Jian-Min Yuan, Philip Lazarus, Matthew B. Schabath, Melinda C. Aldrich, Demetrios Albanes, Raymond Mak, David Barbie, Paul Brennan, Rayjean J. Hung, Christopher I. Amos, David C. Christiani, Xihong Lin
Summary: This study prioritizes and characterizes single nucleotide polymorphisms (SNPs) that increase the risk of squamous cell lung cancer by utilizing extensive multiomics data sources and genome-wide functional annotations. The reanalysis of data highlights the impact of SNPs from nuclear factor-kappa B signaling pathway genes and major histocompatibility complex-mediated immune responses on lung cancer. The strategies introduced in this study provide informative and systematic approaches for incorporating genome-wide annotation data in genetic association studies.
GENETIC EPIDEMIOLOGY
(2021)
Article
Oncology
Katelyn M. Atkins, Tafadzwa L. Chaunzwa, Nayan Lamba, Danielle S. Bitterman, Bhupendra Rawal, Jeremy Bredfeldt, Christopher L. Williams, David E. Kozono, Elizabeth H. Baldini, Anju Nohria, Udo Hoffmann, Hugo J. W. L. Aerts, Raymond H. Mak
Summary: This cohort study explores the impact of radiation doses to cardiac substructures on major adverse cardiac events and mortality in patients with locally advanced non-small cell lung cancer. The findings suggest that dose exposure to the left anterior descending coronary artery may be an independent factor associated with adverse cardiac events and mortality, with significant interaction with baseline coronary heart disease status. Further validation and optimization of risk mitigation strategies are needed.
Article
Oncology
Katelyn M. Atkins, Danielle S. Bitterman, Tafadzwa L. Chaunzwa, Christopher L. Williams, Rifaquat Rahman, David E. Kozono, Elizabeth H. Baldini, Hugo J. W. L. Aerts, Balaji K. Tamarappoo, Udo Hoffmann, Anju Nohria, Raymond H. Mak
Summary: This study aimed to assess whether statin therapy is a predictor of overall survival in patients with locally advanced non-small cell lung cancer after thoracic radiation therapy. The results showed that statin use was associated with an increased risk of all-cause mortality but not major adverse cardiac events in these patients.
PRACTICAL RADIATION ONCOLOGY
(2021)
Article
Oncology
Katelyn M. Atkins, Danielle S. Bitterman, Tafadzwa L. Chaunzwa, David E. Kozono, Elizabeth H. Baldini, Hugo J. W. L. Aerts, Balaji K. Tamarappoo, Udo Hoffmann, Anju Nohria, Raymond H. Mak
Summary: This study found that MHD is insufficient to predict LAD V15Gy with confidence, and there is discordance between MHD and LAD V15Gy. For patients with locally advanced NSCLC, isolated low LAD V15Gy can significantly reduce the risk of MACE.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2021)
Review
Oncology
Danielle S. Bitterman, Timothy A. Miller, Raymond H. Mak, Guergana K. Savova
Summary: Natural language processing (NLP) is rapidly developing and widely used, offering the potential to unlock valuable data in clinical free text for medical research. Recent advances in NLP algorithms have led to increased interest in automation tools for information extraction in clinical texts, potentially transforming medical research and practice.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2021)
Article
Multidisciplinary Sciences
Tafadzwa L. Chaunzwa, Ahmed Hosny, Yiwen Xu, Andrea Shafer, Nancy Diao, Michael Lanuti, David C. Christiani, Raymond H. Mak, Hugo J. W. L. Aerts
Summary: The study introduces a radiomics approach to predict NSCLC tumor histology using deep learning on CT data, showing promising results. Besides predicting tumor histology, machine learning classifiers on radiomics features derived from CNNs also demonstrated comparable discriminative performance.
SCIENTIFIC REPORTS
(2021)
Article
Oncology
Diana D. Shi, Kevin X. Liu, Fred Hacker, Glenn J. Hanna, Raymond Y. Kwong, Daniel N. Cagney, Raymond H. Mak, Lisa Singer
Summary: Stereotactic magnetic resonance-guided adaptive radiation therapy offers advantages in treating cardiac metastases, improving tumor visualization, real-time monitoring, and plan adaptation.
PRACTICAL RADIATION ONCOLOGY
(2021)
Article
Cardiac & Cardiovascular Systems
John Whitaker, Raymond H. Mak, Paul C. Zei
Summary: Stereotactic ablative radiotherapy (SABR) has been increasingly used in the management of arrhythmias, particularly ventricular tachycardia (VT). It offers a non-invasive treatment option that can spare patients from lengthy catheter ablation procedures and target substrate that is inaccessible using current techniques. Both pre-clinical and clinical evidence support the potential of cardiac SABR in arrhythmia management.
TRENDS IN CARDIOVASCULAR MEDICINE
(2022)
Article
Surgery
Kayla K. Umemoto, Shahini Ananth, Anthony Ma, Anvay Ullal, Prakash V. A. K. Ramdass, Peter C. Lo, Dinesh Vyas
Summary: This study is a large retrospective study on the application of hydrodissection in laparoscopic cholecystectomy (LC) for gangrenous gallbladders (GGBs). It has shown that hydrodissection can reduce operating time, anesthesia time, length of stay, and conversion to open procedures.
JOURNAL OF SURGICAL RESEARCH
(2023)
Article
Multidisciplinary Sciences
Jakob Weiss, Vineet K. K. Raghu, Dennis Bontempi, David C. C. Christiani, Raymond H. H. Mak, Michael T. T. Lu, Hugo J. W. L. Aerts
Summary: Deep learning can estimate lung disease mortality from a chest x-ray beyond risk factors, which may help to identify individuals at risk in screening and cancer populations.
NATURE COMMUNICATIONS
(2023)
Article
Computer Science, Artificial Intelligence
Zezhong Ye, Jack M. Qian, Ahmed Hosny, Roman Zeleznik, Deborah Plana, Jirapat Likitlersuang, Zhongyi Zhang, Raymond H. Mak, Hugo J. W. L. Aerts, Benjamin H. Kann
Summary: Identifying intravenous contrast enhancement on CT scans is crucial for medical imaging-based artificial intelligence model development. This study developed a deep learning platform using convolutional neural networks to detect contrast enhancement. The researchers found that traditional imaging metadata often lacked complete documentation, requiring manual annotation. The trained model showed high accuracy in detecting contrast enhancement on CT scans across multiple datasets.
RADIOLOGY-ARTIFICIAL INTELLIGENCE
(2022)
Meeting Abstract
Oncology
Elizabeth Loehrer, Jakob Weiss, Raymond H. Mak, Junwei Lu, Andrea Shafer, Michael H. Rosenthal, Hugo J. Aerts, David C. Christiani
Meeting Abstract
Radiology, Nuclear Medicine & Medical Imaging
C. L. Williams, Z. Han, M. Huynh, J. E. Leeman, L. Singer, D. N. Cagney, R. H. Mak, E. Huynh
Meeting Abstract
Radiology, Nuclear Medicine & Medical Imaging
M. Boeck, C. Wei, R. Mak, U. Tedrow, P. Zei, H. Cochet, M. Juhoor, S. Friesen, F. Hacker, J. Bredfeldt